VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Stock Comparison

Sartorius Stedim Biotech S.A. vs Novo Nordisk A/S

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Sartorius Stedim Biotech S.A.

DIM · Euronext Paris

Market cap (USD)$17.8B
Gross margin (TTM)34.7%
Operating margin (TTM)37%
Net margin (TTM)8.9%
SectorHealthcare
IndustryMedical - Instruments & Supplies
CountryFR
Data as of2025-12-28
Moat score
80/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Sartorius Stedim Biotech S.A.'s moat claims, evidence, and risks.

View DIM analysis

Novo Nordisk A/S

NOVOB · Nasdaq Copenhagen

Market cap (USD)$1.3T
Gross margin (TTM)81%
Operating margin (TTM)41.3%
Net margin (TTM)33.1%
SectorHealthcare
IndustryBiotechnology
CountryDK
Data as of2025-12-28
Moat score
85/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Novo Nordisk A/S's moat claims, evidence, and risks.

View NOVOB analysis

Comparison highlights

  • Moat score gap: Novo Nordisk A/S leads (85 / 100 vs 80 / 100 for Sartorius Stedim Biotech S.A.).
  • Segment focus: Sartorius Stedim Biotech S.A. has 2 segments (75% in Sterile single-use bioprocessing consumables); Novo Nordisk A/S has 3 segments (71.1% in Diabetes care).
  • Primary market structure: Oligopoly vs Oligopoly. Pricing power: Strong vs Moderate.
  • Moat breadth: Sartorius Stedim Biotech S.A. has 6 moat types across 3 domains; Novo Nordisk A/S has 5 across 3.

Primary market context

Sartorius Stedim Biotech S.A.

Sterile single-use bioprocessing consumables

Market

Sterile single-use bioprocessing consumables (bags, filters, fluid management components)

Geography

Global

Customer

Biopharmaceutical manufacturers and CDMOs

Role

Consumables supplier (single-use)

Revenue share

75%

Novo Nordisk A/S

Diabetes care

Market

Diabetes pharmaceuticals (GLP-1 for type 2 diabetes, insulin, and related therapies)

Geography

Global

Customer

Payers/providers and patients (via wholesalers/pharmacies/hospitals)

Role

Originator pharma (R&D, regulatory, manufacturing, commercialization)

Revenue share

71.1%

Side-by-side metrics

Sartorius Stedim Biotech S.A.
Novo Nordisk A/S
Ticker / Exchange
DIM - Euronext Paris
NOVOB - Nasdaq Copenhagen
Market cap (USD)
$17.8B
$1.3T
Gross margin (TTM)
34.7%
81%
Operating margin (TTM)
37%
41.3%
Net margin (TTM)
8.9%
33.1%
Sector
Healthcare
Healthcare
Industry
Medical - Instruments & Supplies
Biotechnology
HQ country
FR
DK
Primary segment
Sterile single-use bioprocessing consumables
Diabetes care
Market structure
Oligopoly
Oligopoly
Market share
10%-25% (implied)
33.7% (reported)
HHI estimate
n/a
n/a
Pricing power
Strong
Moderate
Moat score
80 / 100
85 / 100
Moat domains
Demand, Supply, Legal
Legal, Supply, Demand
Last update
2025-12-28
2025-12-28

Moat coverage

Shared moat types

Learning Curve Yield

Sartorius Stedim Biotech S.A. strengths

Installed Base ConsumablesDesign In QualificationCompliance AdvantageSuite BundlingCapex Knowhow Scale

Novo Nordisk A/S strengths

IP Choke PointRegulated Standards PipeCapacity MoatBrand Trust

Segment mix

Sartorius Stedim Biotech S.A. segments

Full profile >

Sterile single-use bioprocessing consumables

Oligopoly

75%

Bioprocessing equipment, systems, and software/services

Oligopoly

25%

Novo Nordisk A/S segments

Full profile >

Diabetes care

Oligopoly

71.1%

Obesity care

Duopoly

22.4%

Rare disease

Oligopoly

6.4%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.